Elevated FOSB-expression; a potential marker of valproate sensitivity in AML

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylase inhibitors (HDIs) are a novel therapeutic class for acute myeloid leukemia (AML).
• Current response rates to HDIs alone are insufficient, necessitating the identification of predictive biomarkers.
• Sodium valproate (VPA) is an HDI with potential in AML treatment.

Purpose of the Study:

• To identify markers associated with clinical responsiveness to valproate (VPA) in patients with acute myeloid leukemia (AML).
• To investigate the role of FOSB expression as a predictive biomarker for VPA sensitivity in AML.

Main Methods:

• A clinical trial involving 20 AML patients treated with VPA in combination therapy.
• In vitro sensitivity assays of patient-derived AML blasts to VPA.
• Microarray analysis and quantitative polymerase chain reaction (qPCR) to assess gene expression, specifically FOSB.
• Functional studies involving FOSB overexpression in K562 myeloid cells.

Main Results:

• Three out of 20 patients achieved clinical remission (1 CR, 2 PR) with VPA combination therapy.
• In vitro VPA sensitivity of leukemic blasts correlated with in vivo response.
• Elevated FOSB expression was identified as a potential marker for VPA sensitivity in primary AML samples and cell lines.
• FOSB overexpression in K562 cells enhanced in vitro sensitivity to VPA.

Conclusions:

• FOSB is a novel, potential biomarker for predicting VPA sensitivity in acute myeloid leukemia (AML).
• Targeting FOSB or utilizing it as a predictive marker may improve the efficacy of VPA-based therapies in AML.
• Further validation of FOSB as a predictive biomarker in larger AML cohorts is warranted.